Vertex Pharmaceuticals is a US biotech company. It is known for cystic fibrosis drugs that treat the cause of the disease. It also offers a gene therapy for sickle cell disease and a non-opioid painkiller. It sells mainly in the US and Europe. As of Oct 11, 2026
As of Oct 11, 2026Fact sheet (from the annual report)Pharmaceutical manufacturers · Boston, USAfull fact sheet
According to the company, it is a global biotechnology company focused on specialty markets and operates in a single segment. It has approved medicines for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain. For cystic fibrosis, the group markets ALYFTREK, TRIKAFTA and KALYDECO, among others. JOURNAVX has been approved in the United States since January 2025 for treating moderate to severe acute pain in adults. For sickle cell disease and transfusion-dependent beta thalassemia, the group offers CASGEVY; in certain markets it can supply it directly to treatment centers. Customers are mainly a few specialty pharmacies and specialty distributors as well as certain large wholesalers in the US market.
Our own calculation from the exchange’s daily candles, as of Oct 26, 2026. “All-time” applies since the start of this series, not to the whole market. Changes in percent; the TradingView chart shows prices. “Today” = change of the last trading day versus the previous day. Not investment advice.
Fundamentals · Analysis method
Growth, margin and debt compared with the sector – in detail in the fundamental analysis further down. The chart shows the candles without a buy zone.
Growth: greenMargin: greenDebt: gray
Load chart from TradingView
This transfers data (including your IP address) to TradingView, also to the USA. More in the Privacy policy.
With a free account: save the buy zone shown for yourself (stop and targets from Watcher). It stays visible even if the zone changes later. Log in
· Sign up
Fundamental analysis
SEC filing (10-K, 10-Q)Required reports of listed companies to the US Securities and Exchange Commission (SEC): 10-K is the annual report, 10-Q the quarterly report, 20-F the annual report of foreign companies. We show the figures of the first filing.Example: 10-K for the fiscal year ending Sep 27, 2025, filed on Oct 31, 2025.More in the Academy: Lesson revenue, profit and margin
Vertex Pharmaceuticals · Sector Health Care · amounts in USD
Information only – does not affect our buy zones, not investment advice. Source: SEC filings, As of Feb 13, 2026.
In short
Light green: Revenue grew over 5 years (+14.1% per year), at least as fast as the sector median.
Light green: Net income (total) grew over 5 years (+7.8% per year), at least as fast as the sector median; per share +8.3% per year.
Light green: Net margin 32.9%, above the sector median (12.9%).
Light red: Profit in 8 of 10 fiscal years.
Summarized from the lights below. Describes the reported figures – not a recommendation to buy or sell.
RevenueNet incomeNet margin (below)in USD
−5B05B10B15B
2016Fiscal year 2016 (Jan 1, 2016 – Dec 31, 2016): Revenue 1.7B USD · Net income −112.1M USD · Net margin −6.6%
2017Fiscal year 2017 (Jan 1, 2017 – Dec 31, 2017): Revenue 2.5B USD · Net income 263.5M USD · Net margin 10.6%
2018Fiscal year 2018 (Jan 1, 2018 – Dec 31, 2018): Revenue 3.0B USD · Net income 2.1B USD · Net margin 68.8%
2019Fiscal year 2019 (Jan 1, 2019 – Dec 31, 2019): Revenue 4.2B USD · Net income 1.2B USD · Net margin 28.3%
2020Fiscal year 2020 (Jan 1, 2020 – Dec 31, 2020): Revenue 6.2B USD · Net income 2.7B USD · Net margin 43.7%
2021Fiscal year 2021 (Jan 1, 2021 – Dec 31, 2021): Revenue 7.6B USD · Net income 2.3B USD · Net margin 30.9%
2022Fiscal year 2022 (Jan 1, 2022 – Dec 31, 2022): Revenue 8.9B USD · Net income 3.3B USD · Net margin 37.2%
2023Fiscal year 2023 (Jan 1, 2023 – Dec 31, 2023): Revenue 9.9B USD · Net income 3.6B USD · Net margin 36.7%
2024Fiscal year 2024 (Jan 1, 2024 – Dec 31, 2024): Revenue 11.0B USD · Net income −535.6M USD · Net margin −4.9%
2025Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 12.0B USD · Net income 4.0B USD · Net margin 32.9%
Margin
−7%11%69%28%44%31%37%37%−5%33%
RevenueNet incomeNet margin (below)in USD
−4B−2B02B4B
Q3/23Quarter Q3/23 (Jul 1, 2023 – Sep 30, 2023): Revenue 2.5B USD · Net income 1.0B USD · Net margin 41.7%
Q4/23Quarter Q4/23 (Oct 1, 2023 – Dec 31, 2023): Revenue 2.5B USD · Net income 968.8M USD · Net margin 38.5% · Q4 derived (year minus 9 months), may be distorted by restatements
Q1/24Quarter Q1/24 (Jan 1, 2024 – Mar 31, 2024): Revenue 2.7B USD · Net income 1.1B USD · Net margin 40.9%
Q2/24Quarter Q2/24 (Apr 1, 2024 – Jun 30, 2024): Revenue 2.6B USD · Net income −3.6B USD · Net margin −135.8%
Q3/24Quarter Q3/24 (Jul 1, 2024 – Sep 30, 2024): Revenue 2.8B USD · Net income 1.0B USD · Net margin 37.7%
Q4/24Quarter Q4/24 (Oct 1, 2024 – Dec 31, 2024): Revenue 2.9B USD · Net income 913.0M USD · Net margin 31.4% · Q4 derived (year minus 9 months), may be distorted by restatements
Q1/25Quarter Q1/25 (Jan 1, 2025 – Mar 31, 2025): Revenue 2.8B USD · Net income 646.3M USD · Net margin 23.3%
Q2/25Quarter Q2/25 (Apr 1, 2025 – Jun 30, 2025): Revenue 3.0B USD · Net income 1.0B USD · Net margin 34.8%
Q3/25Quarter Q3/25 (Jul 1, 2025 – Sep 30, 2025): Revenue 3.1B USD · Net income 1.1B USD · Net margin 35.2%
Q4/25Quarter Q4/25 (Oct 1, 2025 – Dec 31, 2025): Revenue 3.2B USD · Net income 1.2B USD · Net margin 37.3% · Q4 derived (year minus 9 months), may be distorted by restatements
Q1/26Quarter Q1/26 (Jan 1, 2026 – Mar 31, 2026): Revenue 3.0B USD · Net income 1.0B USD · Net margin 34.5%
Q2/26Quarter Q2/26 (Apr 1, 2026 – Jun 30, 2026): Revenue 3.3B USD · Net income 1.1B USD · Net margin 33.0%
Margin
42%38%41%−136%38%31%23%35%35%37%35%33%
Earnings per shareUSD per share
−5.0005.00101520
2016Fiscal year 2016 (Jan 1, 2016 – Dec 31, 2016): Earnings per share −0.46 USD
2017Fiscal year 2017 (Jan 1, 2017 – Dec 31, 2017): Earnings per share 1.04 USD
2018Fiscal year 2018 (Jan 1, 2018 – Dec 31, 2018): Earnings per share 8.09 USD
2019Fiscal year 2019 (Jan 1, 2019 – Dec 31, 2019): Earnings per share 4.51 USD
2020Fiscal year 2020 (Jan 1, 2020 – Dec 31, 2020): Earnings per share 10.29 USD
2021Fiscal year 2021 (Jan 1, 2021 – Dec 31, 2021): Earnings per share 9.01 USD
2022Fiscal year 2022 (Jan 1, 2022 – Dec 31, 2022): Earnings per share 12.82 USD
2023Fiscal year 2023 (Jan 1, 2023 – Dec 31, 2023): Earnings per share 13.89 USD
2024Fiscal year 2024 (Jan 1, 2024 – Dec 31, 2024): Earnings per share −2.08 USD
2025Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Earnings per share 15.32 USD
Q4/25Quarter Q4/25 (Oct 1, 2025 – Dec 31, 2025): Earnings per share not reported separately for Q4
Q1/26Quarter Q1/26 (Jan 1, 2026 – Mar 31, 2026): Earnings per share 4.02 USD
Q2/26Quarter Q2/26 (Apr 1, 2026 – Jun 30, 2026): Earnings per share 4.31 USD
No reported values for “Dividend per share” in this interval.
No reported values for “Dividend per share” in this interval.
Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 12.0B USD · Net income 4.0B USD · Net margin 32.9%
Key figures with traffic lights
Each light follows a simple, disclosed rule. The comparison is with the sector median Sector medianThe middle value of all companies in a sector: half are above it, half below. Unlike the average, single outliers hardly distort it.Example: Margins 4%, 8%, 10%, 12%, 60% → median 10%, average 18.8%.More in the Academy: Lesson putting the P/E in context of all 63 symbols in the Health Care sector on our list (current members of the S&P 500 and other lists).
Revenue growth
Growth per year (CAGR)The average annual growth rate over several years, as if the value had grown equally strongly every year. Individual good or bad years even out in it.Example: Revenue €100m → €161m in 5 years → (161 ÷ 100) to the power of 1/5 − 1 = 10% per year.More in the Academy: Lesson debt, dividends and growth
Light green: above sector
+14.1%per year, last 5 years
Sector Health Care: median +7.8% (60 symbols)
What does this mean? Revenue: over 5 years it grew by 14.1% per year on average – at least as fast as the median company in the sector (+7.8%).
Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.
Net income (total)
Growth per year (CAGR)The average annual growth rate over several years, as if the value had grown equally strongly every year. Individual good or bad years even out in it.Example: Revenue €100m → €161m in 5 years → (161 ÷ 100) to the power of 1/5 − 1 = 10% per year.More in the Academy: Lesson debt, dividends and growth
Light green: above sector
+7.8%per year, last 5 years
Sector Health Care: median +7.5% (46 symbols)
per share: +8.3% per year (5 years, split-adjusted)
What does this mean? Total net income: over 5 years it grew by 7.8% per year on average – at least as fast as the median company in the sector (+7.5%).
Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.
What does this mean? Of every 100 USD in revenue, 32.94 USD remained as profit – at least as much as the median company in the sector (12.9%). Five years ago the margin was 43.7%.
Light rule: Green: at least the sector median (without a sector comparison: profit) · Yellow: profit, but below the median · Red: loss.
Debt / equity
Debt-to-equity ratioFinancial debt (loans, bonds) divided by equity. A high value amplifies good and bad years alike. The key figures bar in the chart only uses long-term financial debt.Example: Financial debt €300m, equity €500m → 0.6.More in the Academy: Lesson debt, dividends and growth
Light gray: not available
–latest balance sheet
Sector Health Care: median 0.66 (40 symbols)
What does this mean? No usable figure: reported financial debt or positive equity for the same balance sheet date is missing.
Light rule: Green: at most the sector median · Yellow: up to twice the median · Red: more than twice · Gray: without a sector comparison.
Payout ratio
Payout ratioThe share of profit that a company pays out as a dividend. Above 100% it pays out more than it earns.Example: Dividend €1, earnings per share €2.50 → payout ratio 40%.More in the Academy: Lesson debt, dividends and growth
Light gray: none found
–Dividend / earnings per share
Sector Health Care: median 28% (31 symbols)
What does this mean? The loaded SEC filings of the last two fiscal years contain no dividend per share. Either the company pays none, or it reports it under a different tag.
Light rule: Green: up to 60% of earnings · Yellow: up to 100% · Red: more than earnings or a dividend despite a loss · Gray for real estate (REITs). The sector median is for comparison only.
Profitable years
Profitable yearsHow many of the last fiscal years ended with a profit rather than a loss on the bottom line. The figure shows how consistently a company earns.Example: Profit in 9 of 10 years → one loss year.More in the Academy: Lesson revenue, profit and margin
Light red: 2 loss years
8 of 10fiscal years with a profit
What does this mean? In 8 of the last 10 fiscal years the bottom line showed a profit. 2 years ended with a loss.
Light rule: Green: profit in every year · Yellow: one loss year · Red: several loss years (at least 3 years needed).
Last fiscal year and 13F
Information, not a trading signal · Source: SEC EDGAR
Revenue (FY)
12.0B USD
Revenue vs. prior year
+8.9%
Net income (FY)
4.0B USD
Net income vs. prior year
–
EPS (FY)
15.32 USD
13F funds with a position
2 of 9
Funds vs. prior quarter
+2
Shares held vs. prior quarter
–
Fiscal year to Dec 31, 2025 · 10-K filed Feb 13, 2026 · Price-based figures (P/E, P/S, dividend yield, market cap) only when logged in. · Values as first reported; debt = reported financial debt (US GAAP: long-term).13F: reporting date Jun 30, 2026, 9 tracked funds have filed (latest Aug 14, 2026), filed with up to 45 days of delay. Stock positions only; comparison with Mar 31, 2026 only across funds that filed for both quarters.
All figures as a table
Fiscal years (amounts in USD, per share in USD)
Year
End
Revenue
Net income
Margin
Earnings per share
Dividend per share
Payout
2025
Dec 31, 2025
12.0B
4.0B
32.9%
15.32
–
–
2024
Dec 31, 2024
11.0B
−535.6M
−4.9%
−2.08
–
–
2023
Dec 31, 2023
9.9B
3.6B
36.7%
13.89
–
–
2022
Dec 31, 2022
8.9B
3.3B
37.2%
12.82
–
–
2021
Dec 31, 2021
7.6B
2.3B
30.9%
9.01
–
–
2020
Dec 31, 2020
6.2B
2.7B
43.7%
10.29
–
–
2019
Dec 31, 2019
4.2B
1.2B
28.3%
4.51
–
–
2018
Dec 31, 2018
3.0B
2.1B
68.8%
8.09
–
–
2017
Dec 31, 2017
2.5B
263.5M
10.6%
1.04
–
–
2016
Dec 31, 2016
1.7B
−112.1M
−6.6%
−0.46
–
–
Quarters (amounts in USD, per share in USD)
Quarter
End
Revenue
Net income
Margin
Earnings per share
Dividend per share
Payout
Q2/26
Jun 30, 2026
3.3B
1.1B
33.0%
4.31
–
–
Q1/26
Mar 31, 2026
3.0B
1.0B
34.5%
4.02
–
–
Q4/25*
Dec 31, 2025
3.2B
1.2B
37.3%
–
–
–
Q3/25
Sep 30, 2025
3.1B
1.1B
35.2%
4.20
–
–
Q2/25
Jun 30, 2025
3.0B
1.0B
34.8%
3.99
–
–
Q1/25
Mar 31, 2025
2.8B
646.3M
23.3%
2.49
–
–
Q4/24*
Dec 31, 2024
2.9B
913.0M
31.4%
–
–
–
Q3/24
Sep 30, 2024
2.8B
1.0B
37.7%
4.01
–
–
Q2/24
Jun 30, 2024
2.6B
−3.6B
−135.8%
−13.92
–
–
Q1/24
Mar 31, 2024
2.7B
1.1B
40.9%
4.21
–
–
Q4/23*
Dec 31, 2023
2.5B
968.8M
38.5%
–
–
–
Q3/23
Sep 30, 2023
2.5B
1.0B
41.7%
3.97
–
–
* Q4 derived: fiscal year minus the 9-month value (EPS cannot be derived this way); may be distorted by restatements.
How we calculate: values as first reported to the SEC (later corrections are left out), a fixed order of reporting tags per figure, partial sums are never added up. Growth per year Growth per year (CAGR)The average annual growth rate over several years, as if the value had grown equally strongly every year. Individual good or bad years even out in it.Example: Revenue €100m → €161m in 5 years → (161 ÷ 100) to the power of 1/5 − 1 = 10% per year.More in the Academy: Lesson debt, dividends and growth over 5 years (otherwise 3 years). Quarters are labeled by the calendar quarter in which they end.
Insiders
Insider transactionsExecutives, directors and major shareholders (over 10%) of US companies report their own transactions in their company’s stock to the SEC within two business days (Form 4). Purchases in the market count as more meaningful than sales (often taxes, estate planning).Example: Three executives acquire stock worth a total of 2 million USD within two weeks → “purchases by several insiders”.More in the Academy: Glossary
Jun 26, 2026Bozic CarmenOfficerOpen-market sale · 10b5-1 plan596 shares · $287.6K · SEC
Jun 18, 2026Bozic CarmenOfficerOpen-market sale · 10b5-1 plan1,020 shares · $471.4K · SEC
Jun 15, 2026Bozic CarmenOfficerOpen-market sale · 10b5-1 plan4,062 shares · $1.8M · SEC
Source: mandatory filings with the SEC (Form 4), open-market purchases and sales only. General information, not investment advice.
Trend score +55
Price vs. EMA 50+15
Price vs. EMA 200+15
EMA 50 vs. EMA 200+20
ADX (trend strength)+0
Highs and lows-10
Relative strength+15
Volatility and trend strength
ADX 14 (trend strength)17.5
Rel. strength 60 d+6.6%
ATR ATR (Average True Range)The average range per trading day over the last 14 days. It makes distances comparable, whether a stock costs 10 or 1,000.Example: ATR 2.50 at a price of 100: 0.4 ATR is 1.00, i.e. 1%.More in the Academy: Lesson ATR and moving averages as price values only when logged in.